Personalized treatment choices for advanced ovarian cancer
Improving Treatment Selection in Advanced Ovarian Cancer
A computer simulation will help doctors pick the best order and types of surgery, chemotherapy, and targeted drugs for women with advanced ovarian cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11338684 on NIH RePORTER |
What this research studies
If you have advanced ovarian cancer, this project builds a computer model that uses past patient outcomes, tumor features, and treatment details to compare different care paths. The model will simulate combinations such as timing of surgery versus chemotherapy, different chemotherapy regimens, and use of targeted drugs like PARP inhibitors. It will also factor in tumor mutations and treatment costs to project long-term survival and side effects. The goal is to suggest personalized treatment plans that balance survival, toxicity, and expense.
Who could benefit from this research
Good fit: Women with newly diagnosed advanced (stage III or IV) ovarian cancer or those facing decisions about surgery, chemotherapy sequencing, or targeted therapy are the ideal candidates.
Not a fit: People with early-stage ovarian cancer or whose treatment choices are already fixed by urgent clinical needs are unlikely to benefit directly from this work.
Why it matters
Potential benefit: This could help doctors choose treatments that improve long-term survival, reduce harmful side effects, and avoid unnecessary costs for women with advanced ovarian cancer.
How similar studies have performed: Related decision-modeling approaches have informed treatment choices in other cancers, and PARP inhibitors are already effective in some patients with specific tumor mutations.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Pandharipande, Pari Vijay — University of Pennsylvania
- Study coordinator: Pandharipande, Pari Vijay
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.